News headlines about Dynavax Technologies (NASDAQ:DVAX) have trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dynavax Technologies earned a news impact score of 0.13 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.9758995532704 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Dynavax Technologies (NASDAQ DVAX) opened at $19.25 on Friday. Dynavax Technologies has a fifty-two week low of $3.70 and a fifty-two week high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. The business had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. Dynavax Technologies had a negative return on equity of 51.46% and a negative net margin of 41,750.95%. The company’s revenue was down 68.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.90) EPS. analysts predict that Dynavax Technologies will post -1.72 EPS for the current fiscal year.
A number of brokerages have recently issued reports on DVAX. BidaskClub downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Royal Bank of Canada reissued an “outperform” rating and set a $28.00 target price (up from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. ValuEngine raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. Cantor Fitzgerald began coverage on Dynavax Technologies in a research note on Friday, September 15th. They set an “overweight” rating and a $24.00 target price for the company. Finally, Cowen reissued a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a research note on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. Dynavax Technologies has an average rating of “Buy” and a consensus target price of $25.17.
In related news, insider Robert Coffman sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $18.90, for a total value of $141,750.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 2.90% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Dynavax Technologies (DVAX) Receives Daily Coverage Optimism Rating of 0.13” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/12/17/dynavax-technologies-dvax-receives-daily-coverage-optimism-rating-of-0-13.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.